Table 1.
Comparison of the basic information of the training and validation sets
| Clinical characters | Level | Training set (n = 98) | Validation set (n = 41) | p value |
|---|---|---|---|---|
| Age (years, mean [SD]) | – | 54.28 (10.57) | 54.61 (12.25) | 0.872 |
| Menopause (%) | False | 31 (32.3) | 13 (32.5) | 1 |
| True | 65 (67.7) | 27 (67.5) | ||
| T stage (%) | 1 | 48 (49.0) | 14 (34.1) | 0.206 |
| 2 | 46 (46.9) | 26 (63.4) | ||
| 3 | 4 (4.1) | 1 (2.4) | ||
| N stage (%) | 0 | 56 (58.3) | 27 (65.9) | 0.226 |
| 1 | 23 (24.0) | 12 (29.3) | ||
| 2 | 12 (12.5) | 2 (4.9) | ||
| 3 | 5 (5.2) | 0 (0.0) | ||
| Stromal TILs (%) | High | 56 (57.1) | 23 (56.1) | 1 |
| Low | 42 (42.9) | 18 (43.9) | ||
| Ki-67 [mean (SD)] | – | 56.99 (21.90) | 64.27 (26.14) | 0.094 |
| Molecular subtype (%) | BLIS | 29 (29.6) | 13 (31.7) | 0.709 |
| IM | 21 (21.4) | 9 (22.0) | ||
| LAR | 17 (17.3) | 8 (19.5) | ||
| MES | 16 (16.3) | 3 (7.3) | ||
| Unknown | 15 (15.3) | 8 (19.5) |
SD standard deviation, BLIS basal-like immune-suppressed, IM immunomodulatory, LAR luminal androgen receptor, MES mesenchymal-like